234 related articles for article (PubMed ID: 15895376)
1. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid.
Pilatrino C; Cilloni D; Messa E; Morotti A; Giugliano E; Pautasso M; Familiari U; Cappia S; Pelicci PG; Lo Coco F; Saglio G; Guerrasio A
Cancer; 2005 Jul; 104(1):101-9. PubMed ID: 15895376
[TBL] [Abstract][Full Text] [Related]
2. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N
Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213
[TBL] [Abstract][Full Text] [Related]
3. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia.
Kuendgen A; Schmid M; Schlenk R; Knipp S; Hildebrandt B; Steidl C; Germing U; Haas R; Dohner H; Gattermann N
Cancer; 2006 Jan; 106(1):112-9. PubMed ID: 16323176
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
Bug G; Ritter M; Wassmann B; Schoch C; Heinzel T; Schwarz K; Romanski A; Kramer OH; Kampfmann M; Hoelzer D; Neubauer A; Ruthardt M; Ottmann OG
Cancer; 2005 Dec; 104(12):2717-25. PubMed ID: 16294345
[TBL] [Abstract][Full Text] [Related]
5. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia.
Cimino G; Lo-Coco F; Fenu S; Travaglini L; Finolezzi E; Mancini M; Nanni M; Careddu A; Fazi F; Padula F; Fiorini R; Spiriti MA; Petti MC; Venditti A; Amadori S; Mandelli F; Pelicci PG; Nervi C
Cancer Res; 2006 Sep; 66(17):8903-11. PubMed ID: 16951208
[TBL] [Abstract][Full Text] [Related]
6. Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients.
Bellos F; Mahlknecht U
Onkologie; 2008 Nov; 31(11):629-33. PubMed ID: 19145098
[TBL] [Abstract][Full Text] [Related]
7. Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study.
Giagounidis AA; Haase S; Germing U; Schlegelberger B; Wilkens L; Büsche G; Kreipe HH; Wysk J; Grips KH; Grabenhorst U; Rothmann F; Lübbert M; Ganser A; Aivado M; Heinsch M; Aul C
Ann Hematol; 2005 Jun; 84(6):389-94. PubMed ID: 15785949
[TBL] [Abstract][Full Text] [Related]
8. Valproic acid for the treatment of myeloid malignancies.
Kuendgen A; Gattermann N
Cancer; 2007 Sep; 110(5):943-54. PubMed ID: 17647267
[TBL] [Abstract][Full Text] [Related]
9. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.
Heidel F; Cortes J; Rücker FG; Aulitzky W; Letvak L; Kindler T; Huber C; Döhner H; Kantarjian H; Fischer T
Cancer; 2007 Mar; 109(5):907-14. PubMed ID: 17285599
[TBL] [Abstract][Full Text] [Related]
10. A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid.
Ryningen A; Stapnes C; Lassalle P; Corbascio M; Gjertsen BT; Bruserud O
Leuk Res; 2009 Jun; 33(6):779-87. PubMed ID: 19007987
[TBL] [Abstract][Full Text] [Related]
11. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia.
Raffoux E; Chaibi P; Dombret H; Degos L
Haematologica; 2005 Jul; 90(7):986-8. PubMed ID: 15996941
[TBL] [Abstract][Full Text] [Related]
12. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
[TBL] [Abstract][Full Text] [Related]
13. Effect of combination therapy with all-trans-retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes.
Ganser A; Seipelt G; Verbeek W; Ottmann OG; Maurer A; Kolbe K; Hess U; Elsner S; Reutzel R; Wörmann B
Leukemia; 1994 Mar; 8(3):369-75. PubMed ID: 7510354
[TBL] [Abstract][Full Text] [Related]
14. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
[TBL] [Abstract][Full Text] [Related]
15. Phase I-II study of 13-cis-retinoic acid in myelodysplastic syndrome.
Greenberg BR; Durie BG; Barnett TC; Meyskens FL
Cancer Treat Rep; 1985 Dec; 69(12):1369-74. PubMed ID: 3865701
[TBL] [Abstract][Full Text] [Related]
16. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid.
Kuendgen A; Strupp C; Aivado M; Bernhardt A; Hildebrandt B; Haas R; Germing U; Gattermann N
Blood; 2004 Sep; 104(5):1266-9. PubMed ID: 15155466
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and toxicity of low-dose melphalan in myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia.
Robak T; Szmigielska-Kapłon A; Urbańska-Ryś H; Chojnowski K; Wrzesień-Kuś A
Neoplasma; 2003; 50(3):172-5. PubMed ID: 12937849
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome.
Raffoux E; Cras A; Recher C; Boëlle PY; de Labarthe A; Turlure P; Marolleau JP; Reman O; Gardin C; Victor M; Maury S; Rousselot P; Malfuson JV; Maarek O; Daniel MT; Fenaux P; Degos L; Chomienne C; Chevret S; Dombret H
Oncotarget; 2010 May; 1(1):34-42. PubMed ID: 21293051
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P
J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646
[TBL] [Abstract][Full Text] [Related]
20. Treatment with valproic acid, all-trans retinoic acid (ATRA) and theophyllamine for 9 days caused a persistent increase in peripheral blood platelet counts for a patient with acute myelogenous leukemia.
Stapnes C; Ryningen A; Gjertsen BT; Bruserud Ø
Acta Oncol; 2006; 45(3):346-9. PubMed ID: 16644583
[No Abstract] [Full Text] [Related]
[Next] [New Search]
